Compare BTBT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | BTBT | ELVN |
|---|---|---|
| Price | $2.20 | $25.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.50 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 32.2M | 1.5M |
| Earning Date | 03-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $105,703,143.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $90.95 | N/A |
| P/E Ratio | $3.35 | ★ N/A |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $1.69 | $13.30 |
| 52 Week High | $4.55 | $29.98 |
| Indicator | BTBT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 65.30 |
| Support Level | $2.02 | $24.29 |
| Resistance Level | $2.37 | $28.69 |
| Average True Range (ATR) | 0.15 | 2.59 |
| MACD | 0.00 | 0.31 |
| Stochastic Oscillator | 45.35 | 73.64 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.